Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda in recurrent high grade neuroendocrine carcinoma
NCT03190213Phase 2Terminated
- Sponsor
- University of Utah
- Start
- Dec 2017
- Primary completion
- Dec 2018
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in neuroendocrine carcinoma (NEC), sponsored by University of Utah. Primary endpoint: Overall Response Rate at 230 days. Started Dec 2017; status: terminated.
02
Drugs
03
Conditions
neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on NCT03190213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03190213.